Related Experiment Videos
Approaches to the treatment of bladder cancer at Stanford
1Division of Medical Oncology, Stanford University, CA.
Abstract:
The treatment of bladder cancer is one of the most active areas of clinical cancer research. The use of new classes of intravesical agents, such as the interferons, and analogues of effective intravesical chemotherapies, such as epirubicin, the 4-epimer of doxorubicin, show promise of controlling the sequela of this common urologic problem. In metastatic transitional cell carcinoma, the CMV regimen holds promise of palliation for many and or long-term remission for some patients with advanced bladder cancer.
Insights
New intravesical agents like interferons and epirubicin show promise for bladder cancer treatment. The CMV regimen offers palliation and remission for advanced metastatic transitional cell carcinoma.
Area of Science:
- Urologic oncology
- Clinical cancer research
- Pharmacological therapies
Background:
- Bladder cancer treatment is a dynamic field of clinical research.
- Intravesical therapies are crucial for managing this common urologic malignancy.
- Advanced disease necessitates effective systemic and local treatment strategies.
Purpose of the Study:
- To review promising new intravesical agents for bladder cancer.
- To evaluate the potential of epirubicin and interferons in bladder cancer therapy.
- To assess the efficacy of the CMV regimen in metastatic transitional cell carcinoma.
Main Methods:
- Review of current clinical research in bladder cancer.
- Analysis of novel intravesical chemotherapies and biological agents.
- Evaluation of treatment outcomes for metastatic transitional cell carcinoma.
Main Results:
- Interferons and epirubicin (a doxorubicin analogue) demonstrate potential as intravesical agents.
- The CMV regimen shows promise for symptom relief (palliation) in advanced bladder cancer.
- Some patients with metastatic transitional cell carcinoma may achieve long-term remission with the CMV regimen.
Conclusions:
- Novel intravesical agents offer new therapeutic avenues for bladder cancer.
- The CMV regimen provides a viable option for palliation and potential remission in metastatic disease.
- Continued research into advanced bladder cancer treatments is essential.